MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - miscellaneous
- DR. DATSONS LABS - ALEMBIC PHARMA
DR. DATSONS LABS vs ALEMBIC PHARMA - Comparison Results
Current Valuations
| DR. DATSONS LABS | ALEMBIC PHARMA | DR. DATSONS LABS/ ALEMBIC PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | -10.9 | 17.4 | - | View Chart |
| P/BV | x | 0.2 | 6.9 | 2.4% | View Chart |
| Dividend Yield | % | 0.0 | 0.6 | - |
Financials
 DR. DATSONS LABS  ALEMBIC PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. DATSONS LABS Mar-14 |
ALEMBIC PHARMA Mar-19 |
DR. DATSONS LABS/ ALEMBIC PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 664 | 18.9% | |
| Low | Rs | 31 | 412 | 7.5% | |
| Sales per share (Unadj.) | Rs | 133.0 | 208.7 | 63.7% | |
| Earnings per share (Unadj.) | Rs | 0.2 | 31.0 | 0.5% | |
| Cash flow per share (Unadj.) | Rs | 6.6 | 37.1 | 17.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 5.50 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.0 | 0.0% | |
| Book value per share (Unadj.) | Rs | 128.8 | 144.2 | 89.3% | |
| Shares outstanding (eoy) | m | 31.66 | 188.52 | 16.8% | |
| Bonus/Rights/Conversions | FCCB | - | - | ||
| Price / Sales ratio | x | 0.6 | 2.6 | 22.8% | |
| Avg P/E ratio | x | 516.1 | 17.4 | 2,972.6% | |
| P/CF ratio (eoy) | x | 11.8 | 14.5 | 81.7% | |
| Price / Book Value ratio | x | 0.6 | 3.7 | 16.3% | |
| Dividend payout | % | 0 | 17.7 | 0.0% | |
| Avg Mkt Cap | Rs m | 2,477 | 101,461 | 2.4% | |
| No. of employees | `000 | NA | NA | - | |
| Total wages/salary | Rs m | 56 | 7,467 | 0.7% | |
| Avg. sales/employee | Rs Th | NM | NM | - | |
| Avg. wages/employee | Rs Th | NM | NM | - | |
| Avg. net profit/employee | Rs Th | NM | NM | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,211 | 39,347 | 10.7% | |
| Other income | Rs m | 79 | 94 | 83.9% | |
| Total revenues | Rs m | 4,289 | 39,441 | 10.9% | |
| Gross profit | Rs m | 569 | 8,736 | 6.5% | |
| Depreciation | Rs m | 204 | 1,152 | 17.7% | |
| Interest | Rs m | 430 | 184 | 233.7% | |
| Profit before tax | Rs m | 13 | 7,493 | 0.2% | |
| Minority Interest | Rs m | 0 | 11 | 0.0% | |
| Prior Period Items | Rs m | -2 | -93 | 1.9% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 6 | 1,568 | 0.4% | |
| Profit after tax | Rs m | 5 | 5,844 | 0.1% | |
| Gross profit margin | % | 13.5 | 22.2 | 60.8% | |
| Effective tax rate | % | 48.0 | 20.9 | 229.6% | |
| Net profit margin | % | 0.1 | 14.9 | 0.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 6,852 | 19,577 | 35.0% | |
| Current liabilities | Rs m | 6,711 | 14,896 | 45.0% | |
| Net working cap to sales | % | 3.3 | 11.9 | 28.1% | |
| Current ratio | x | 1.0 | 1.3 | 77.7% | |
| Inventory Days | Days | 161 | 90 | 179.2% | |
| Debtors Days | Days | 318 | 45 | 702.2% | |
| Net fixed assets | Rs m | 3,673 | 27,097 | 13.6% | |
| Share capital | Rs m | 317 | 377 | 84.0% | |
| "Free" reserves | Rs m | 3,761 | 26,811 | 14.0% | |
| Net worth | Rs m | 4,078 | 27,188 | 15.0% | |
| Long term debt | Rs m | 1,671 | 4,993 | 33.5% | |
| Total assets | Rs m | 12,633 | 47,778 | 26.4% | |
| Interest coverage | x | 1.0 | 41.7 | 2.5% | |
| Debt to equity ratio | x | 0.4 | 0.2 | 223.1% | |
| Sales to assets ratio | x | 0.3 | 0.8 | 40.5% | |
| Return on assets | % | 3.4 | 12.6 | 27.3% | |
| Return on equity | % | 0.1 | 21.5 | 0.5% | |
| Return on capital | % | 7.7 | 23.6 | 32.5% | |
| Exports to sales | % | 22.9 | 0 | - | |
| Imports to sales | % | 14.3 | 0 | - | |
| Exports (fob) | Rs m | 964 | NA | - | |
| Imports (cif) | Rs m | 602 | NA | - | |
| Fx inflow | Rs m | 964 | 19,453 | 5.0% | |
| Fx outflow | Rs m | 607 | 6,065 | 10.0% | |
| Net fx | Rs m | 357 | 13,388 | 2.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,345 | 8,120 | 16.6% | |
| From Investments | Rs m | -2,256 | -7,556 | 29.9% | |
| From Financial Activity | Rs m | -1,200 | 590 | -203.2% | |
| Net Cashflow | Rs m | -2,111 | 1,153 | -183.0% | |
Share Holding
| Indian Promoters | % | 4.5 | 74.1 | 6.1% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.0 | 2.9 | - | |
| FIIs | % | 1.4 | 9.1 | 14.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 94.1 | 13.9 | 677.0% | |
| Shareholders | 20,807 | 49,328 | 42.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. DATSONS LABS With: J.B.CHEMICALS SUVEN LIFE SCIENCES WYETH CADILA HEALTHCARE VENUS REMEDIES
Compare DR. DATSONS LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views on News
ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)
Jan 19, 2021 | Updated on Jan 19, 2021For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)
Oct 23, 2020 | Updated on Oct 23, 2020For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Shares of Oxygen Suppliers in Focus Amid Rising Demand for Oxygen (Company Info)
Apr 20, 2021In this article, we discuss the hype around Oxygen supplier stocks and a little known NBFC company, which has rallied 150% in less than a month.
Nazara Technologies IPO: Should You Apply? (IPO)
Mar 17, 2021Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?
ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)
Jan 23, 2020 | Updated on Jan 23, 2020For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games?(The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
Why Did the Market Crash on Monday?(Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DR. DATSONS LABS SHARE PRICE
May 21, 2015 (Close)
TRACK DR. DATSONS LABS
- Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. DATSONS LABS
DR. DATSONS LABS - WOCKHARDT COMPARISON
COMPARE DR. DATSONS LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.